Cullinan Associates Inc. Purchases 1,348 Shares of Becton, Dickinson and Company (NYSE:BDX)

Posted by on Mar 21st, 2023

Cullinan Associates Inc. lifted its position in Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 122.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,448 shares of the medical instruments supplier’s stock after acquiring an additional 1,348 shares during the period. Cullinan Associates Inc.’s holdings in Becton, Dickinson and were worth $623,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Radnor Capital Management LLC raised its position in shares of Becton, Dickinson and by 3.9% in the 4th quarter. Radnor Capital Management LLC now owns 1,064 shares of the medical instruments supplier’s stock worth $270,000 after acquiring an additional 40 shares in the last quarter. Tranquilli Financial Advisor LLC raised its position in shares of Becton, Dickinson and by 4.8% in the 2nd quarter. Tranquilli Financial Advisor LLC now owns 912 shares of the medical instruments supplier’s stock worth $225,000 after acquiring an additional 42 shares in the last quarter. Physicians Financial Services Inc. increased its position in Becton, Dickinson and by 1.0% during the 3rd quarter. Physicians Financial Services Inc. now owns 4,517 shares of the medical instruments supplier’s stock valued at $1,007,000 after buying an additional 46 shares in the last quarter. Valmark Advisers Inc. increased its position in Becton, Dickinson and by 1.0% during the 3rd quarter. Valmark Advisers Inc. now owns 4,800 shares of the medical instruments supplier’s stock valued at $1,070,000 after buying an additional 46 shares in the last quarter. Finally, Guardian Wealth Advisors LLC increased its position in Becton, Dickinson and by 5.6% during the 3rd quarter. Guardian Wealth Advisors LLC now owns 893 shares of the medical instruments supplier’s stock valued at $199,000 after buying an additional 47 shares in the last quarter. Institutional investors own 87.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. The Goldman Sachs Group reduced their price objective on Becton, Dickinson and from $319.00 to $272.00 and set a “buy” rating for the company in a research report on Wednesday, November 23rd. Piper Sandler raised their price objective on Becton, Dickinson and from $245.00 to $260.00 and gave the company a “neutral” rating in a research report on Thursday, February 2nd. Morgan Stanley raised their price objective on Becton, Dickinson and from $290.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, February 3rd. Bank of America raised Becton, Dickinson and from a “neutral” rating to a “buy” rating and raised their price objective for the company from $250.00 to $290.00 in a research report on Tuesday, January 3rd. Finally, StockNews.com started coverage on Becton, Dickinson and in a report on Thursday, March 16th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $271.89.

Becton, Dickinson and Stock Up 1.2 %

Becton, Dickinson and stock opened at $238.49 on Tuesday. The firm has a market cap of $67.71 billion, a price-to-earnings ratio of 45.00, a PEG ratio of 2.49 and a beta of 0.53. Becton, Dickinson and Company has a 12 month low of $215.90 and a 12 month high of $277.29. The company has a current ratio of 1.07, a quick ratio of 0.60 and a debt-to-equity ratio of 0.56. The stock has a fifty day simple moving average of $244.27 and a two-hundred day simple moving average of $241.46.

Becton, Dickinson and (NYSE:BDX – Get Rating) last released its quarterly earnings results on Thursday, February 2nd. The medical instruments supplier reported $2.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.30. The firm had revenue of $4.59 billion for the quarter, compared to the consensus estimate of $4.59 billion. Becton, Dickinson and had a return on equity of 13.52% and a net margin of 8.47%. The company’s revenue for the quarter was down 2.8% on a year-over-year basis. During the same period last year, the business posted $3.64 EPS. Equities analysts predict that Becton, Dickinson and Company will post 12.19 EPS for the current fiscal year.

Becton, Dickinson and Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 31st. Stockholders of record on Friday, March 10th will be paid a $0.91 dividend. The ex-dividend date of this dividend is Thursday, March 9th. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.53%. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 68.68%.

Insider Transactions at Becton, Dickinson and

In other news, EVP Richard Byrd sold 1,421 shares of the firm’s stock in a transaction on Friday, February 3rd. The stock was sold at an average price of $248.60, for a total value of $353,260.60. Following the transaction, the executive vice president now directly owns 4,119 shares in the company, valued at approximately $1,023,983.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.31% of the company’s stock.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.

Read More

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Get Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.